Page 2 - Biontech Group News Today

COVID-19 vaccine franchise focused on vaccine adaptation readiness ahead of the fall season and advancing next generation vaccine candidates and combinationsBioNTech and partner OncoC4 plan to start a

Are not sent the registration documents with the access data without being requested to do so, we will be pleased to send them to you on request. 3.Procedure for... | April 13, 2023

Michael Horowicz: Good morning and afternoon. Thank you for joining us today for BioNTechs fourth quarter and full year 2022 earnings call.

Investegate announcements from BioNTech SE, BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update

Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well as first half 2022 revenues of €9.6 billion, net profit of €5.4 billion

The Commonwealth Heads of Government Meeting (CHOGM) 2022 that draw to the end over the weekend left an indelible memory to Rwandans and nearly 4000 guests who attended the meeting in Kigali, the capital of Rwanda.

President Paul Kagame has laid the foundation stone for the construction of a vaccine manufacturing plant in Kigali Special Economic Zone located in Masoro of Gasabo District.

First quarter revenues of €6.4 billion1, net income of €3.7 billion and fully diluted earnings per share of €14.24 ($15.972)Reiterates BioNTech COVID-19 2022 vaccine revenue guidance of €13 billion to

BNTX earnings call for the period ending December 31, 2021.

Investegate announcements from BioNTech SE, BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update